Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
In metastatic castration-resistant prostate cancer, the combination of CRLX101, a nanoparticle camptothecin formulation, with enzalutamide (NCT03531827) explored synergistic cytotoxic and anti-androgenic effects but faced early discontinuation due to limited efficacy
By entering the subcutaneous fat layer, nearly 90% of the medication becomes bioavailable, leading to more predictable levels in the bloodstream
Its also approved to reduce the risk of major cardiovascular events, like death, heart attack, or stroke, in adults with known heart disease and obesity or overweight
and have not been demonstrated to the FDA to be safe or effective for their intended use
US$ 26.61
US$ 24.62
US$ 28.52
US$ 28.10
US$ 29.20
